16 results on '"Ariane Vieira Scarlatelli Macedo"'
Search Results
2. Diretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024
- Author
-
Fabio Fernandes, Marcus V. Simões, Edileide de Barros Correia, Fabiana Goulart Marcondes-Braga, Otavio Rizzi Coelho-Filho, Cláudio Tinoco Mesquita, Wilson Mathias Junior, Murillo de Oliveira Antunes, Edmundo Arteaga-Fernández, Carlos Eduardo Rochitte, Felix José Alvarez Ramires, Silvia Marinho Martins Alves, Marcelo Westerlund Montera, Renato Delascio Lopes, Mucio Tavares de Oliveira Junior, Fernando Luis Scolari, Walkiria Samuel Avila, Manoel Fernandes Canesin, Edimar Alcides Bocchi, Fernando Bacal, Lidia Zytynski Moura, Eduardo Benchimol Saad, Mauricio Ibrahim Scanavacca, Bruno Pereira Valdigem, Manuel Nicolas Cano, Alexandre Antonio Cunha Abizaid, Henrique Barbosa Ribeiro, Pedro Alves Lemos Neto, Gustavo Calado de Aguiar Ribeiro, Fabio Biscegli Jatene, Ricardo Ribeiro Dias, Luis Beck-da-Silva, Luis Eduardo Paim Rohde, Marcelo Imbroinise Bittencourt, Alexandre da Costa Pereira, José Eduardo Krieger, Humberto Villacorta Junior, Wolney de Andrade Martins, José Albuquerque de Figueiredo Neto, Juliano Novaes Cardoso, Carlos Alberto Pastore, Ieda Biscegli Jatene, Ana Cristina Sayuri Tanaka, Viviane Tiemi Hotta, Minna Moreira Dias Romano, Denilson Campos de Albuquerque, Ricardo Mourilhe-Rocha, Ludhmila Abrahão Hajjar, Fabio Sandoli de Brito Junior, Bruno Caramelli, Daniela Calderaro, Pedro Silvio Farsky, Alexandre Siciliano Colafranceschi, Ibraim Masciarelli Francisco Pinto, Marcelo Luiz Campos Vieira, Luiz Claudio Danzmann, Silvio Henrique Barberato, Charles Mady, Martino Martinelli Filho, Ana Flavia Malheiros Torbey, Pedro Vellosa Schwartzmann, Ariane Vieira Scarlatelli Macedo, Silvia Moreira Ayub Ferreira, Andre Schmidt, Marcelo Dantas Tavares de Melo, Moysés Oliveira Lima Filho, Andrei C. Sposito, Flávio de Souza Brito, Andreia Biolo, Vagner Madrini Junior, Stephanie Itala Rizk, and Evandro Tinoco Mesquita
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2024
- Full Text
- View/download PDF
3. Posicionamento sobre Doença Isquêmica do Coração – A Mulher no Centro do Cuidado – 2023
- Author
-
Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Daniela do Carmo Rassi, Érika Olivier Vilela Bragança, Lidia Zytynski Moura, Magaly Arrais, Milena dos Santos Barros Campos, Viviana Guzzo Lemke, Walkiria Samuel Avila, Alexandre Jorge Gomes de Lucena, André Luiz Cerqueira de Almeida, Andréa Araujo Brandão, Andrea Dumsch de Aragon Ferreira, Andreia Biolo, Ariane Vieira Scarlatelli Macedo, Breno de Alencar Araripe Falcão, Carisi Anne Polanczyk, Carla Janice Baister Lantieri, Celi Marques-Santos, Claudia Maria Vilas Freire, Denise Pellegrini, Elizabeth Regina Giunco Alexandre, Fabiana Goulart Marcondes Braga, Fabiana Michelle Feitosa de Oliveira, Fatima Dumas Cintra, Isabela Bispo Santos da Silva Costa, José Sérgio Nascimento Silva, Lara Terra F. Carreira, Lucelia Batista Neves Cunha Magalhães, Luciana Diniz Nagem Janot de Matos, Marcelo Heitor Vieira Assad, Marcia M. Barbosa, Marconi Gomes da Silva, Maria Alayde Mendonça Rivera, Maria Cristina de Oliveira Izar, Maria Elizabeth Navegantes Caetano Costa, Maria Sanali Moura de Oliveira Paiva, Marildes Luiza de Castro, Marly Uellendahl, Mucio Tavares de Oliveira Junior, Olga Ferreira de Souza, Ricardo Alves da Costa, Ricardo Quental Coutinho, Sheyla Cristina Tonheiro Ferro da Silva, Sílvia Marinho Martins, Simone Cristina Soares Brandão, Susimeire Buglia, Tatiana Maia Jorge de Ulhôa Barbosa, Thais Aguiar do Nascimento, Thais Vieira, Valquíria Pelisser Campagnucci, and Antonio Carlos Palandri Chagas
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2023
- Full Text
- View/download PDF
4. Posicionamento sobre a Saúde Cardiovascular nas Mulheres – 2022
- Author
-
Glaucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Celi Marques-Santos, Maria Elizabeth Navegantes Caetano Costa, Regina Coeli Marques de Carvalho, Cláudia Maria Vilas Freire, Lucelia Batista Neves Cunha Magalhães, Ludhmila Abrahão Hajjar, Maria Alayde Mendonça Rivera, Marildes Luiza de Castro, Walkiria Samuel Avila, Alexandre Jorge Gomes de Lucena, Andréa Araujo Brandão, Ariane Vieira Scarlatelli Macedo, Carla Janice Baister Lantieri, Carisi Anne Polanczyk, Carlos Japhet da Matta Albuquerque, Daniel Born, Eduardo Belisário Falcheto, Érika Olivier Vilela Bragança, Fabiana Goulart Marcondes Braga, Fernanda M. Consolim Colombo, Ieda Biscegli Jatene, Isabela Bispo Santos da Silva Costa, Ivan Romero Rivera, Jaqueline Ribeiro Scholz, José Xavier de Melo Filho, Magaly Arrais dos Santos, Maria Cristina de Oliveira Izar, Maria Fátima Azevedo, Maria Sanali Moura, Milena dos Santos Barros Campos, Olga Ferreira de Souza, Orlando Otávio de Medeiros, Sheyla Cristina Tonheiro Ferro da Silva, Stéphanie Itala Rizk, Thais de Carvalho Vieira Rodrigues, Thaís Rocha Salim, and Viviana de Mello Guzzo Lemke
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2022
- Full Text
- View/download PDF
5. Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial
- Author
-
André Luiz Malavasi Longo de Oliveira MD, MSc, Renata Fernanda de Oliveira Pereira MD, Leandro Barile Agati Ph.D, Camilla Moreira Ribeiro Ph.D, Gabrielly Yukimi Kawamura Suguiura, Claudia Helena Cioni MD, Marilsa Bermudez MD, Márcia Bermudez Pirani MD, Roberto Augusto Caffaro MD, Ph.D, Valter Castelli, Valéria Cristina Resende Aguiar MD, Giuliano Giova Volpiani MD, Adilson Paschoa MD, Ph.D, Ariane Vieira Scarlatelli Macedo MD, Pedro Gabriel Melo de Barros e Silva MD, Ph.D, João Carlos de Campos Guerra MD, Ph.D, Jawed Fareed Ph.D, Renato Delascio Lopes MD, Ph.D, and Eduardo Ramacciotti MD, Ph.D
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prevention after major gynecological cancer surgery might be an alternative to parenteral low-molecular-weight heparin (LMWH). Patients undergoing major gynecological cancer surgery were randomized at hospital discharge to receive rivaroxaban 10 mg once daily or enoxaparin 40 mg once daily for 30 days. The primary efficacy outcome was a combination of symptomatic VTE and VTE-related death or asymptomatic VTE at day 30. The primary safety outcome was the incidence of major or clinically relevant nonmajor bleeding. Two hundred and twenty-eight patients were enrolled and randomly assigned to receive rivaroxaban (n = 114)or enoxaparin (n = 114). The trial was stopped due to a lower-than-expected event rate. The primary efficacy outcome occurred in 3.51% of patients assigned to rivaroxaban and in 4.39% of patients assigned to enoxaparin (relative risk 0.80, 95% CI 0.22 to 2.90; p = 0.7344). Patients assigned to rivaroxaban had no primary bleeding event, and 3 patients (2.63%) in the enoxaparin group had a major or CRNM bleeding event (hazard ratio, 0.14; 95% CI, 0.007 to 2.73; P = 0.1963). In patients undergoing major gynecological cancer surgery, thromboprophylaxis with rivaroxaban 10 mg daily for 30 days had similar rates of thrombotic and bleeding events compared to parenteral enoxaparin 40 mg daily. While the power is limited due to not reaching the intended sample size, our results support the hypothesis that DOACs might be an attractive alternative strategy to LMWH to prevent VTE in this high-risk population.
- Published
- 2022
- Full Text
- View/download PDF
6. Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
- Author
-
Fernanda Salles Seguro, Carolina Maria Pinto Domingues Carvalho Silva, Carla Maria Boquimpani de Moura, Monika Conchon, Laura Fogliatto, Vaneuza Araujo Moreira Funke, André Abdo, Ariane Vieira Scarlatelli Macedo, Marilia Harumi Higushi dos Santos, and José Francisco Kerr Saraiva
- Subjects
Cardiovascular diseases ,Leukemia, myeloid ,Protein kinase inhibitors ,Risk factors ,Risk management ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and from the perspective of hematology consultation.In the first medical appointment, the CV risk factors should be identified to perform the baseline risk stratification, based on the Brazilian Guideline of Dyslipidemia and Atherosclerosis Prevention Update (risk levels: very high, high, intermediate and low).Once stratified, the treatment of the CV risk factors should be administered. If the patient presents risk factors, such as hypertension, diabetes, renal disease, smoking and hypercholesterolemia, the evaluation and initial treatment may be done by the hematologist, being an option the request for evaluation by a specialist. If the patient has a history of previous CV disease, we recommend referral to a specialist.As the CV risk score is dynamic and the control of risk factors can reduce the patient risk, this expert consensus recommends that the re-evaluation of the CV risk after the baseline should be performed at 3 months, 6 months and 12 months. After this period, it should be done annually and, for specific patients, at the clinician’s discretion.The evaluation of the baseline CV risk and the safe administration of a TKI allow the patient to benefit from the maximum treatment, avoiding unwanted effects.
- Published
- 2021
- Full Text
- View/download PDF
7. Diretriz Brasileira de Cardio-oncologia – 2020
- Author
-
Ludhmila Abrahão Hajjar, Isabela Bispo Santos da Silva da Costa, Marcelo Antônio Cartaxo Queiroga Lopes, Paulo Marcelo Gehm Hoff, Maria Del Pilar Estevez Diz, Silvia Moulin Ribeiro Fonseca, Cristina Salvadori Bittar, Marília Harumi Higuchi dos Santos Rehder, Stephanie Itala Rizk, Dirceu Rodrigues Almeida, Gustavo dos Santos Fernandes, Luís Beck-da-Silva, Carlos Augusto Homem de Magalhães Campos, Marcelo Westerlund Montera, Sílvia Marinho Martins Alves, Júlia Tizue Fukushima, Maria Verônica Câmara dos Santos, Carlos Eduardo Negrão, Thiago Liguori Feliciano da Silva, Silvia Moreira Ayub Ferreira, Marcus Vinicius Bolivar Malachias, Maria da Consolação Vieira Moreira, Manuel Maria Ramos Valente Neto, Veronica Cristina Quiroga Fonseca, Maria Carolina Feres de Almeida Soeiro, Juliana Barbosa Sobral Alves, Carolina Maria Pinto Domingues Carvalho Silva, João Sbano, Ricardo Pavanello, Ibraim Masciarelli F. Pinto, Antônio Felipe Simão, Marianna Deway Andrade Dracoulakis, Ana Oliveira Hoff, Bruna Morhy Borges Leal Assunção, Yana Novis, Laura Testa, Aristóteles Comte de Alencar Filho, Cecília Beatriz Bittencourt Viana Cruz, Juliana Pereira, Diego Ribeiro Garcia, Cesar Higa Nomura, Carlos Eduardo Rochitte, Ariane Vieira Scarlatelli Macedo, Patricia Tavares Felipe Marcatti, Wilson Mathias Junior, Evanius Garcia Wiermann, Renata do Val, Helano Freitas, Anelisa Coutinho, Clarissa Maria de Cerqueira Mathias, Fernando Meton de Alencar Camara Vieira, André Deeke Sasse, Vanderson Rocha, José Antônio Franchini Ramires, and Roberto Kalil Filho
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2020
- Full Text
- View/download PDF
8. Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy
- Author
-
Fernanda Andrade Orsi, Erich V. De Paula, Fernanda de Oliveira Santos, Marcelo Melzer Teruchkin, Dirceu Hamilton Cordeiro Campêlo, Tayana Teixeira Mello, Maria Chiara Chindamo, Ariane Vieira Scarlatelli Macedo, Ana Thereza Rocha, Eduardo Ramacciotti, Ana Clara Kneese Nascimento, Joyce Annichino-Bizzacchi, Dayse Maria Lourenco, João Carlos de Campos Guerra, Suely Meireles Rezende, and Cyrillo Cavalheiro Filho
- Subjects
Venous thromboembolism ,Coronavirus disease 2019 ,Coagulopathy ,Prevention ,Treatment ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Hemostatic abnormalities and thrombotic risk associated with coronavirus disease 2019 (COVID-19) are among the most discussed topics in the management of this disease. The aim of this position paper is to provide the opinion of Brazilian experts on the thromboprophylaxis and management of thrombotic events in patients with suspected COVID-19, in the sphere of healthcare in Brazil. To do so, the Brazilian Society of Thrombosis and Hemostasis (BSTH) and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) have constituted a panel of experts to carefully review and discuss the available evidence about this topic. The data discussed in this document was reviewed by May 9, 2020. Recommendations and suggestions reflect the opinion of the panel and should be reviewed periodically as new evidence emerges.
- Published
- 2020
- Full Text
- View/download PDF
9. Implications for Clinical Practice from a Multicenter Survey of Heart Failure Management Centers
- Author
-
Edimar Alcides Bocchi, Henrique Turin Moreira, Juliana Sanajotti Nakamuta, Marcus Vinicius Simões, Alberto de Almeida Las Casas, Altamiro Reis da Costa, Amberson Vieira de Assis, André Rodrigues Durães, Antonio Carlos Pereira-Barretto, Antonio Delduque de Araujo Ravessa, Ariane Vieira Scarlatelli Macedo, Bruno Biselli, Carolina Maria Nogueira Pinto, Conrado Roberto Hoffmann Filho, Costantino Roberto Costantini, Dirceu Rodrigues Almeida, Edval Gomes dos Santos Jr, Erwin Soliva Junior, Estevão Lanna Figueiredo, Felipe Neves de Albuquerque, Felipe Paulitsch, Fernando Carvalho Neuenschwander, José Albuquerque de Figueiredo Neto, Flavio de Souza Brito, Heno Ferreira Lopes, Humberto Villacorta, João David de Souza Neto, João Mariano Sepulveda, José Carlos Aidar Ayoub, José F. Vilela-Martin, Juliano Novaes Cardoso, Laercio Uemura, Lidia Zytynski Moura, Lilia Nigro Maia, Lucia Brandão de Oliveira, Lucimir Maia, Luís Beck da Silva, Luís Henrique Wolff Gowdak, Luiz Claudio Danzmann, Marcus Andrade, Maria Christiane Valeria Braga Braile-Sternieri, Maria da Consolação Vieira Moreira, Olimpio R França Neto, Otavio Rizzi Coelho Filho, Paulo Frederico Esteves, Priscila Raupp-da-Rosa, Ricardo Jorge de Queiroz e Silva, Ricardo Mourilhe-Rocha, Ruy Felipe Melo Viégas, Salvador Rassi, Sandrigo Mangili, Sergio Emanuel Kaiser, Silvia Marinho Martins, and Vitor Sergio Kawabata
- Subjects
Heart Failure ,Disease Management Program ,Education Monitoring ,Clinical Decision-Making ,Multidisciplinary Treatment ,Medicine (General) ,R5-920 - Abstract
OBJECTIVES: This observational, cross-sectional study based aimed to test whether heart failure (HF)-disease management program (DMP) components are influencing care and clinical decision-making in Brazil. METHODS: The survey respondents were cardiologists recommended by experts in the field and invited to participate in the survey via printed form or email. The survey consisted of 29 questions addressing site demographics, public versus private infrastructure, HF baseline data of patients, clinical management of HF, performance indicators, and perceptions about HF treatment. RESULTS: Data were obtained from 98 centers (58% public and 42% private practice) distributed across Brazil. Public HF-DMPs compared to private HF-DMP were associated with a higher percentage of HF-DMP-dedicated services (79% vs 24%; OR: 12, 95% CI: 94-34), multidisciplinary HF (MHF)-DMP [84% vs 65%; OR: 3; 95% CI: 1-8), HF educational programs (49% vs 18%; OR: 4; 95% CI: 1-2), written instructions before hospital discharge (83% vs 76%; OR: 1; 95% CI: 0-5), rehabilitation (69% vs 39%; OR: 3; 95% CI: 1-9), monitoring (44% vs 29%; OR: 2; 95% CI: 1-5), guideline-directed medical therapy-HF use (94% vs 85%; OR: 3; 95% CI: 0-15), and less B-type natriuretic peptide (BNP) dosage (73% vs 88%; OR: 3; 95% CI: 1-9), and key performance indicators (37% vs 60%; OR: 3; 95% CI: 1-7). In comparison to non- MHF-DMP, MHF-DMP was associated with more educational initiatives (42% vs 6%; OR: 12; 95% CI: 1-97), written instructions (83% vs 68%; OR: 2: 95% CI: 1-7), rehabilitation (69% vs 17%; OR: 11; 95% CI: 3-44), monitoring (47% vs 6%; OR: 14; 95% CI: 2-115), GDMT-HF (92% vs 83%; OR: 3; 95% CI: 0-15). In addition, there were less use of BNP as a biomarker (70% vs 84%; OR: 2; 95% CI: 1-8) and key performance indicators (35% vs 51%; OR: 2; 95% CI: 91,6) in the non-MHF group. Physicians considered changing or introducing new medications mostly when patients were hospitalized or when observing worsening disease and/or symptoms. Adherence to drug treatment and non-drug treatment factors were the greatest medical problems associated with HF treatment. CONCLUSION: HF-DMPs are highly heterogeneous. New strategies for HF care should consider the present study highlights and clinical decision-making processes to improve HF patient care.
- Published
- 2021
- Full Text
- View/download PDF
10. Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
- Author
-
Érique José F. Peixoto de Miranda MD, PhD, Thamy Takahashi Pharm B., Felipe Iwamoto Pharm B., Suzete Yamashiro DDS, Eliana Samano MD, MBA, Ariane Vieira Scarlatelli Macedo MD, MSc, and Eduardo Ramacciotti MD, PhD
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Data on drug–drug interactions (DDI) of antineoplastic drugs with anticoagulants is scarce. We aim to evaluate factors associated with DDI of antineoplastic and supportive care drugs with anticoagulants resulting in modification of pharmacokinetics of these last mentioned. A literature review on DDI databases and summaries of products characteristics (SmPC) was done. Drug–drug interactions of 257 antineoplastic and supportive care drugs with direct oral anticoagulants (DOACs), warfarin, enoxaparin, or fondaparinux were categorized as no clinically significant expected DDI, potentially weak DDI, potentially clinically significant DDI, and recommendation against coadministration. Logistic regression models were performed to analyze the association between the dependent variable potentially clinically significant interaction/recommendation against coadministration and the mechanisms of DDI. Of the 1799 associations, 84.4% were absence of DDI, 3.6% potentially weak DDI, 10.2% potentially clinically relevant DDI, and 2.0% recommendation against coadministration. Warfarin has higher DDI potential than other anticoagulants. Enoxaparin and fondaparinux have fewer DDI than others. There was no difference between DOACs. Drug–drug interactions with apixaban and rivaroxaban was independently associated with the absence of CYP3A4 competition, P-glycoprotein inhibition, CYP3A4 induction, and drug class of tyrosine kinase inhibitors. Drug–drug interactions with dabigatran and edoxaban was associated with inhibition of P-glycoprotein and tyrosine kinase inhibitors. Warfarin, induction of CYP3A4, and inhibition of CYP2C9. Enoxaparin and fondaparinux, only tyrosine kinase inhibitors. Direct oral anticoagulants did not differ regarding DDI with antineoplastic agents. Warfarin presented more DDI than other anticoagulants. P-glycoprotein inhibition and CYP3A4 induction were independently associated with DDI of antineoplastic agents with DOACs.
- Published
- 2020
- Full Text
- View/download PDF
11. Tratamento Direcionado ao Sistema Renina-Angiotensina-Aldosterona na Obesidade
- Author
-
Ariane Vieira Scarlatelli Macedo
- Subjects
Obesidade ,Doenças Cardiovasculares ,Prevalência ,Insuficiência Cardíaca ,Hipertrofia Ventricular Esquerda ,Sistema Renina-Angiotensina ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2020
- Full Text
- View/download PDF
12. Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy
- Author
-
Márcio Vinícius Lins de Barros, Ariane Vieira Scarlatelli Macedo, Sebastian Imre Sarvari, Monica Hermont Faleiros, Patricia Tavares Felipe, Jose Luiz Padilha Silva, and Thor Edvardsen
- Subjects
Ventricular Dysfunction, Left ,Drug Therapy ,Cardiotoxicity ,Breast Neoplasms ,Anthracyclines ,Trastuzumab ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background: Chemotherapeutic agents of anthracyclines class and humanized monoclonal antibodies are effective treatments for breast cancer, however, they present a potential risk of cardiotoxicity. Several predictors have been recognized as predictors in the development of cardiac toxicity, and the evaluation of left ventricular segmental wall motion abnormalities (LVSWMA) has not been studied. Objective: To analyze prospectively the role of LVSWMA among echocardiographic parameters in the prediction of development of cardiotoxicity in breast cancer patients undergoing treatment with chemotherapy. Methods: Prospective cohort of patients diagnosed with breast cancer and in chemotherapy treatment with potential cardiotoxicity medications including doxorubicin and trastuzumab. Transthoracic echocardiograms including speckle tracking strain echocardiography were performed at standard times before, during and after the treatment to assess the presence (or lack thereof) of cardiotoxicity. Cardiotoxicity was defined by a 10% decrease in the left ventricular ejection fraction, on at least one echocardiogram. Multivariate logistic regression models were used to verify the predictors related to the occurrence of cardiotoxicity over time. Results: Of the 112 patients selected (mean age 51,3 ± 12,9 years), 18 participants (16.1%) had cardiotoxicity. In the multivariate analysis using the logistic regression model, those with LVWMA (OR = 6.25 [CI 95%: 1.03; 37.95], p < 0,05), LV systolic dimension (1.34 [CI 95%: 1.01; 1.79], p < 0,05) and global longitudinal strain by speckle tracking (1.48 [CI 95%: 1.02; 2.12], p < 0,05) were strongly associated with cardiotoxicity. Conclusion: In the present study, we showed that LVWMA, in addition to global longitudinal strains, were strong predictors of cardiotoxicity and could be useful in the risk stratification of these patients.
- Published
- 2018
- Full Text
- View/download PDF
13. Caso 01/2006: insuficiência cardíaca progressiva em homem de 44 anos de idade
- Author
-
Tiago Senra Garcia dos Santos, Ariane Vieira Scarlatelli Macedo, Paulo J Moffa, Maria Clementina Giorgi, Léa Maria Macruz Ferreira Demarchi, and Jussara Bianchi Castelli
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2006
- Full Text
- View/download PDF
14. Infarto fatal do miocárdio em mulher de 88 anos de idade Fatal myocardial infarction in a 88-year-old woman
- Author
-
Ariane Vieira Scarlatelli Macedo, Paulo Jorge Moffa, Cesar José Grupi, Eulógio Emílio Martinez Filho, Petter Libby, and Paulo Sampaio Gutierrez
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2005
- Full Text
- View/download PDF
15. Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities – Systematic Review
- Author
-
Andréa de Melo Leite, Ariane Vieira Scarlatelli Macedo, Antonio José Lagoeiro Jorge, and Wolney de Andrade Martins
- Subjects
Neoplasias da Mama/tratamento farmacológico ,Indicadores de Morbimortalidade ,Aspirina ,Tamoxifeno ,Cloridrato de Raloxifeno ,Doenças Cardiovasculares/prevenção & controle ,Moduladores Seletivos do Receptor Estrogênio ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Breast cancer is the most frequently diagnosed tumor in women worldwide, with a significant impact on morbidity and mortality. Chemotherapy and hormone therapy have significantly reduced mortality; however, the adverse effects are significant. Aspirin has been incorporated into clinical practice for over 100 years at a low cost, making it particularly attractive as a potential agent in breast cancer prevention and as an adjunct treatment to endocrine therapy in the prophylaxis of cardiovascular complications. The objective of this study was to evaluate the role of aspirin in reducing the incidence of breast cancer and to evaluate the impact of its use on morbidity and mortality and reduction of cardiovascular events as adjuvant therapy during breast cancer treatment with selective estrogen receptor modulators. A systematic review was performed using the PRISMA methodology and PICO criteria, based on the MEDLINE, EMBASE and LILACS databases. The original articles of clinical trials, cohort, case-control studies and meta-analyses published from January 1998 to June 2017, were considered. Most studies showed an association between the use of selective estrogen receptor modulators and the increase in thromboembolic events. The studies suggest a protective effect of aspirin for cardiovascular events during its concomitant use with selective estrogen receptor modulators and in the prevention of breast cancer. This systematic review suggests that aspirin therapy combines the benefit of protection against cardiovascular events with the potential reduction in breast cancer risk, and that the evaluation of the benefits of the interaction of endocrine therapy with aspirin should be further investigated.
- Full Text
- View/download PDF
16. Brazilian Society of Cardiology - The Women’s Letter
- Author
-
Glaucia Maria Moraes de Oliveira, Fátima Elizabeth Fonseca de Oliveira Negri, Nadine Oliveira Clausell, Maria da Consolação V. Moreira, Olga Ferreira de Souza, Ariane Vieira Scarlatelli Macedo, Barbara Campos Abreu Marino, Carisi Anne Polanczyk, Carla Janice Baister Lantieri, Celi Marques-Santos, Cláudia Maria Vilas Freire, Deborah Christina Nercolini, Fatima Cristina Monteiro Pedroti, Imara Correia de Queiroz Barbosa, Magaly Arrais dos Santos, Maria Christiane Valéria Braga Braile, Maria Sanali Moura de Oliveira Paiva, Marianna Deway Andrade Dracoulakis, Narriane Chaves Holanda, Patricia Toscano Rocha Rolim, Roberta Tavares Barreto Teixeira, Sandra Mattos, Sheyla Cristina Tonheiro Ferro da Silva, Simone Cristina Soares Brandão, Viviana de Mello Guzzo Lemke, and Marcelo Antônio Cartaxo Queiroga Lopes
- Subjects
Women ,Medicine/ trends ,Demography ,Cardiovascular Diseases/prevention and control ,Societies, Medical ,Management Quality Circles ,Risk Factors ,Prevalence ,Education, Medical ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.